Table 1.
|
Pfizer-BioNTech |
Moderna |
Health Canada approval |
December 9, 2020 |
December 23, 2020 |
Population |
Ages 16+ |
Ages 18+ |
Dose |
30 mcg of mRNA per 0.3 mL (after dilution) |
100 mcg of mRNA per 0.5 mL (no dilution) |
Schedule |
2 doses, 21 days apart |
2 doses, 28 days apart |
Route of administration |
IM (deltoid) |
IM (deltoid) |
Storage temperature |
–70° Celsius |
–20° Celsius |
Efficacy |
95% |
94.1% |
Number of participants in Phase 3 trial |
44,000 total (22,000 vaccine/22,000 placebo) |
30,413 total (15,206 vaccine/15,207 placebo) |
Side effects |
Mild to moderate flu-like symptoms lasted ~2 days (more commonly after the 2nd dose) |
Mild to moderate flu-like symptoms lasted ~2 days (more commonly after the 2nd dose) |
Contraindications |
Pregnant women; COVID-positive; previous anaphylaxis; allergy to ingredients; immunocompromised; precautions for those with bleeding disorders or on anticoagulant therapy. |
Pregnant women; COVID-positive; previous anaphylaxis; allergy to ingredients; immunocompromised; precautions for those with bleeding disorders or on anticoagulant therapy. |
Source: National Advisory Committee on Immunization webinars (https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/ health-professionals.html#a11)